Sera Prognostics Announces Conference Call and Webcast of Second Quarter Fiscal Year 2025 Financial Results on August 6, 2025

Company Overview - Sera Prognostics Inc. is focused on improving maternal and neonatal health through innovative pregnancy biomarker information [3] - The company aims to provide early pregnancy information to enhance the health of mothers and newborns, thereby reducing healthcare delivery costs [3] - Sera Prognostics is headquartered in Salt Lake City, Utah [3] Financial Results Announcement - The company will report its second quarter fiscal year 2025 financial results on August 6, 2025, after market close [1] - A conference call and live webcast will be held at 5:00 p.m. Eastern Time to discuss operational highlights and financial results [1][2] - A press release detailing the financial results will be distributed before the call [1] PreTRM® Test - The PreTRM® Test is a blood-based biomarker test that predicts the risk of spontaneous preterm birth in asymptomatic singleton pregnancies [5] - It measures proteins in the blood that are highly predictive of preterm birth, allowing for early identification of at-risk women [5] - The test enables personalized clinical decisions based on individual risk during weeks 18 to 20 of pregnancy [5] Preterm Birth Context - Preterm birth, defined as birth before 37 weeks' gestation, is the leading cause of illness and death in newborns [4] - Over the last five years, more than 10% of infants in the U.S. have been born prematurely [4] - The annual healthcare costs associated with managing complications from prematurity in the U.S. were estimated at approximately $25 billion in 2016 [4]